Leukemic stem cells modulate the bone marrow microenvironment

ESH eLearning, María-Victoria Mateos, 233966

Genetics and risk assessment (including clonal evolution and clinical implications in terms of risk assessment)

ESH eLearning, Hervé Avet-Loiseau, 233967

Primary plasma cell leukaemia and extramedullary disease

ESH eLearning, Niels VAN DE DONK, 233968

Geriatric assessment: is it required?

ESH eLearning, Alessandra Larocca, 233969

European guidelines

ESH eLearning, Sonja ZWEEGMAN, 233970

Ongoing trials for newly diagnosed patients not eligible for stem cell transplantation, and frontline treatment when new drugs are not available

ESH eLearning, Kwee Yong, 233971

Induction therapy: triplet, quadruplet?

ESH eLearning, Philippe Moreau, 233972

Geriatric assessment in multiple myeloma: is it required?

ESH eLearning, Alessandra Larocca, 234000

MRD as a response assessment in elderly multiple myeloma

ESH eLearning, Alessandra Larocca, 234001

Vaccines to prevent progression or relapse in multiple myeloma

ESH eLearning, Ann van de Velde, 234002

How do we define a ‘cure’ in myeloma?

ESH eLearning, Annemiek Broijl, 234003

Treatment options for high-risk myeloma

ESH eLearning, Annemiek Broijl, 234004

Smoldering myeloma treatment landscape & MRD negativity

ESH eLearning, Annemiek Broijl, 234005

Dendritic cell vaccine for MM: trial updates with maintenance & checkpoint inhibitor pidilizumab

ESH eLearning, David Avigan, 234006

Investigating vaccines for hem-onc: key questions

ESH eLearning, David Avigan, 234007

What is the role of PET/CT in myeloma management?

ESH eLearning, Elena ZAMAGNI, 234008

Where will we be in MM management 5 years from now?

ESH eLearning, Elena ZAMAGNI, 234009

A host of promising agents for myeloma: melflufen, filanesib, trametinib, selinexor

ESH eLearning, Enrique Ocio, 234010

Immunotherapeutics against multiple myeloma: it's all about BCMA

ESH eLearning, Enrique Ocio, 234011

Are BCL2 and MCL1 inhibitors the key against myeloma?

ESH eLearning, Enrique Ocio, 234012

The evolving imaging of multiple myeloma

ESH eLearning, Evangelos Terpos, 234013

Real world data for len/dex in second-line myeloma: what does this tell us?

ESH eLearning, Evangelos Terpos, 234015

Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM

ESH eLearning, Evangelos Terpos, 234016

Treatment sequencing in multiple myeloma: a multitude of options

ESH eLearning, Heinz Ludwig, 234017

Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells

ESH eLearning, Heinz Ludwig, 234018

Smoldering multiple myeloma: what is the current definition & new screening programme

ESH eLearning, Irene Ghobrial, 234019

Opinion: MRD sequencing test approval in multiple myeloma

ESH eLearning, Irene Ghobrial, 234020

CAR T-cells for multiple myeloma: update & what's in store for ASH 2018

ESH eLearning, Jesus Berdeja, 234021

Toxicity profile for CAR T-cells in multiple myeloma

ESH eLearning, Jesus Berdeja, 234022

MRD and disease eradication in myeloma

ESH eLearning, Jesús San Miguel, 234023

Early detection and intervention in myeloma: a critical point

ESH eLearning, Jesús San Miguel, 234024

Continuous vs. fixed duration therapy for multiple myeloma?

ESH eLearning, Jesús San Miguel, 234025

Future treatment combinations for myeloma

ESH eLearning, Kenneth Anderson, 234026

MRD detection in myeloma: approval of NGS assay & questions for the clinic

ESH eLearning, Kenneth Anderson, 234027

Frontline transplant-ineligible MM treatment

ESH eLearning, Kwee Yong, 234028

Combining bortezomib and lenalidomide-based regimens for frontline MM

ESH eLearning, Kwee Yong, 234029

How should smoldering multiple myeloma be monitored?

ESH eLearning, María-Victoria Mateos, 234031

Update on recent smoldering multiple myeloma trials

ESH eLearning, María-Victoria Mateos, 234032

Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma

ESH eLearning, María-Victoria Mateos, 234033

Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma

ESH eLearning, María-Victoria Mateos, 234034

Plasma cell leukemia and extramedullary disease in multiple myeloma

ESH eLearning, Niels van de Donk, 234035

Daratumumab in myeloma update: expanding indications

ESH eLearning, Niels van de Donk, 234036

A novel mechanism of action for daratumumab in myeloma

ESH eLearning, Niels van de Donk, 234037

CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079

ESH eLearning, Niels van de Donk, 234038

MRD negativity using deep sequencing is a major prognostic factor in myeloma

ESH eLearning, Nikhil Munshi, 234039

MRD sequencing test approved for MM in the US

ESH eLearning, Nikhil Munshi, 234040

Genomics shed light on targeted treatment for myeloma

ESH eLearning, Nikhil Munshi, 234041

Frontline treatment of transplant-ineligible MM: a changing landscape

ESH eLearning, Noopur Raje, 234042

Quadruplet regimens and antibodies for newly diagnosed multiple myeloma

ESH eLearning, Noopur Raje, 234043

CAR T-cells for myeloma: an update

ESH eLearning, Noopur Raje, 234044

PVX-410 vaccine for smoldering myeloma

ESH eLearning, Noopur Raje, 234045

Judging the value of a clinical trial in hem-onc

ESH eLearning, Robert Hills, 234047

Opinion: value of MRD as an endpoint in hem-onc clinical trials

ESH eLearning, Robert Hills, 234048

UK NCRI AML17 trial update: everolimus addition for consolidation

ESH eLearning, Robert Hills, 234049

Monoclonal antibodies: current and future potential

ESH eLearning, Saad Usmani, 234050

Targeting BCMA with bispecific antibodies in R/R myeloma

ESH eLearning, Saad Usmani, 234051

Updated POLLUX results for early relapsed myeloma patients

ESH eLearning, Saad Usmani, 234052

Whole genome sequencing opens door for targeted Waldenström’s therapy

ESH eLearning, Steve Treon, 234053

Exploring treatment options against different Waldenström’s mutations

ESH eLearning, Steve Treon, 234054

Mapping the genomic landscape of Waldenström’s Macroglobulinemia

ESH eLearning, Steve Treon, 234055

How to predict response in silico and in vitro?

ESH eLearning, David Weinstock, 234062

Design of innovative clinical trials: still a role for phase III trials?

ESH eLearning, Andrew Davies, 234063

Minimal biological measurement requirements for DLBCL: What do clinicians need to have measured?

ESH eLearning, Lisa RIMSZA, 234061

Rational Targeting of the NuRD Complex For Fetal Hemoglobin Induction 2019 ESH Erythropoiesis

ESH eLearning, Daniel E. Bauer, 265280

Fanconi anaemia

ESH eLearning, Carlo Dufour, 265281

Autoimmune haemolytic anaemias

ESH eLearning, Wilma Barcellini, 265282

Inflammation as a determinant of ineffective erythropoiesis in myelodysplastic syndromes

ESH eLearning, Alan List, 265283

TGF-b pathway inhibitors in low risk MDS

ESH eLearning, Valeria Santini, 265284

New approches to managing sickle cell disease

ESH eLearning, David Rees, 265285

Heme regulation and GATA1

ESH eLearning, Janis Abkowitz, 265286

Gene editing for thalassemia and sickle cell disease

ESH eLearning, Daniel E. Bauer, 265287

Gene therapy for thalassaemia / sickle cell disease

ESH eLearning, Alexis A. Thompson, 265288

Diamond-Blackfan anaemia : genetic and clinical complexity exemplified by 3 cases encountered in clinical practice

ESH eLearning, Marcin Wlodarski, 265289

Which pro-survival BCL-2 family member should be targeted for the treatment of which type of leukaemia or lymphoma

ESH eLearning, Andreas Strasser, 234057

Targeting MALT1 signaling: preclinical data and perspectives in the clinic

ESH eLearning, Daniel KRAPMANN, 234058

The genetic landscape of MCL – more than CyclinD1?

ESH eLearning, Eias CAMPO, 234059

T-NHL: novel targets and therapies - How can we move forward?

ESH eLearning, Norbert SCHMITZ, 234060

Origin of mega/erythroid progenitors in haematopoiesis

ESH eLearning, Claus Nerlov, 265270

Transcription Factors in Erythropoiesis

ESH eLearning, John Strouboulis, 265271

Congenital dyserythropoietic anaemias (CDAs)

ESH eLearning, Achille Iolascon, 265272

Congenital dyserythropoietic anaemias

ESH eLearning, Roberta Russo, 265273

Clinical consequences of ineffective erythropoiesis in myelodysplastic syndromes

ESH eLearning, Aristoteles Giagounidis, 265274

Hereditary haemolytic anaemias

ESH eLearning, Immacolata Andolfo, 265275

Sickle cell disease

ESH eLearning, Mariane de Montalembert, 265276

Acute sickling crisis

ESH eLearning, Lucia De Franceschi, 265277

The relationship between genome structure and function : lessons from the globin loci

ESH eLearning, Douglas Higgs, 265278

Promoter mutations associated with hereditary persistence of fetal haemoglobin either disrupt repressors or create de novo sites for activators

ESH eLearning, Merlin Crossley, 265279

Managing CML in emerging regions: some problems and perspectives

ESH eLearning, Hemant Malhotra, 234664

Long-term survival of patients with chronic phase chronic myeloid leukemia who received autologous stem cell transplantation and further exposed to tyrosine kinase inhibitors

ESH eLearning, Mauricette Michallet, 234801

The technical decline in the rate of CML treatment-free remission in aging countries: the French experience

ESH eLearning, Marc Delord, 257017

Prevalence and outcomes of uncommon BCR-ABL fusion transcripts in patients with CML: data from a single center

ESH eLearning, Qian Jiang, 257018

Aim for the cure: TKI-based chemotherapy for Ph+ ALL

ESH eLearning, Elias Jabbour, 257019

Patients' perspectives on the definition of cure in chronic myeloid leukemia: a US based survey

ESH eLearning, Gemlyn George, 257030

Long-term results of a phase 2 trial of nilotinib 400 Mg twice daily in newly diagnosed patients with chronic phase of chronic myeloid leukemia

ESH eLearning, Lucia Masarova, 257031

Treatment-free remission in patients with chronic phase chronic myeloid leukemia and stable deep molecular response discontinuing dasatinib (DASFREE)

ESH eLearning, Susanne Saussele, 257032

Low-intensity TKI-based therapy for Ph+ ALL

ESH eLearning, Hervé Dombret, 234568

Impact of kinase domain mutations on second line nilotinib therapy In CML chronic phase – Real world data from a developing country perspective

ESH eLearning, Shinto Francis Thekkudan, 234569

Are TKI really safe?

ESH eLearning, C Gambacorti, 234570

Long-term impact of early and deeper molecular response in newly diagnosed CML-CP patients receiving radotinib: three years follow-up of rerise study

ESH eLearning, Young Rok Do, 234571

What prevents the disease from relapsing after TKI discontinuation

ESH eLearning, Satu Mustjoki, 234803